TrialCancer2020

Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.

Carlos E Vargas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.